Kai Dins

Stada’s IPO just got a new headache. Aurobindo circling Zentiva may be “premature”, but the implications are real, as this is where the biggest clash is. Here’s why (in the three most relevant battle-grounds): - Germany → Generics are won through insurer tenders. Zentiva+Aurobindo could bring scale + low-cost API sourcing, intensifying competition in Stada’s home market. - France → The game is portfolio breadth and margin negotiations with wholesalers and pharmacies. With Aurobindo’s backing, Zentiva could offer deeper service packages. - CEE → Zentiva already leads in many markets (thanks to its Sanofi heritage). With more scale and capital, that advantage could widen. IPO or strategic sale angle:  Bain & Cinven want to position Stada as a balanced player: generics + OTC + specialty. But if Aurobindo enters the ring, the generics growth narrative weakens. Investors will scrutinize Stada’s OTC brands and specialty portfolio as the true drivers of resilience. Takeaway: An Aurobindo–Zentiva tie-up wouldn’t sink Stada’s narrative, but it might force a pivot. Less about generics scale, more about brand strength, specialty focus, and execution discipline. The real question:  Will investors buy that pivot or discount it? For Stada, timing may be everything. Waiting to see if Aurobindo actually closes could prove wiser than making irreversible moves too early. One thing is clear:  Stada remains a strong, well-managed company with a diversified portfolio and solid execution track record. That resilience may ultimately be what convinces investors, regardless of who enters the ring. 🔔 Follow for insights  ♻️ Share if you find it interesting #generics #pharma #strategy #zentiva #stada #aurobindo

488

21 Kommentare

The first confidential rebate in Germany will be for Eli Lilly’s Mounjaro (tirzepatide). The company is using a provision in the Medical Research Act of 2024 that applies until the end of June 2028 (and will be evaluated by the Ministry of Health by the end of 2026).   Lilly confirmed to the broadcaster NDR/WDR that it had reached agreement with the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) on “the framework conditions for the contract on the reimbursement amount.”   In a letter sent to physicians in early July, Lilly wrote that it was “the first company in Germany to negotiate a price in accordance with the Medical Research Act that is economical and not published.” It noted that the provision is intended to “give pharmaceutical companies more negotiating leeway without influencing pricing in other countries.” Germany is one of the most frequent comparator countries for international reference pricing in Europe and beyond. Information on rebated prices is generally accessible.   In return for confidentiality, the Medical Research Act requires manufacturers to grant an additional price reduction of 9% after the rebated price has been negotiated with the GKV-Spitzenverband. Lilly noted that this extra saving “substantially improved” the drug’s cost-benefit ratio and will lead to “significant savings” for the healthcare system.   Lilly will notify physicians that the list price “does not play a role in their economic considerations and that this does not stand in the way of a regulation in compliance with the necessary framework conditions, in particular the economic efficiency requirement.” The Social Code Book V specifies that services provided within the statutory health insurance system “must be sufficient, appropriate and economical; they must not exceed what is necessary. Insured persons may not claim for service that are not necessary or uneconomical, the service providers may not provide them and the health insurance funds may not approve them.” #Germany #confidential #rebates #Lilly #Mounjaro

390

17 Kommentare

The most interesting thing this week: AZ's 5 domain Protocol Complexity Tool (PCT) is transforming how we design trials - simpler, faster, and more patient- and site-friendly. Go deeper: (1) AZ team, including our very own Alina Pszczolkowska, developed the 5-domain PCT to quantify and visualize protocol complexity, enabling smarter design decisions. (2) Impact so far: 75% of assessed trials simplified, $10–50M annual cost avoidance, and ~9,500 FTE hours saved. (3) Beyond numbers: PCT fosters early cross-functional collaboration, aligns governance, and improves trial success potential. https://lnkd.in/e_wwCn_r

155

11 Kommentare